NCT04014790View on ClinicalTrials.gov

RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 25, 2019

Primary Completion Date

July 5, 2022

Study Completion Date

April 3, 2023

Conditions
Graft Vs Host DiseaseGraft-versus-host-diseaseAcute-graft-versus-host DiseasePrevention of aGVHD
Interventions
DRUG

RGI-2001

Subjects will receive 6 weekly doses of RGI 2001, 100 μg/kg via IV administration after completion of alloHSCT

DRUG

Standard of Care

Standard of care prophylaxis regimen will be administered according to institutional guidelines

Trial Locations (7)

21201

University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore

33136

University of Miami, Sylvester Comprehensive Cancer Center, Miami

43210

Ohio State University Wexner Medical Center, Columbus

48202

Henry Ford Health System, Detroit

90095

UCLA Medical Center, Los Angeles

02114

Massachusetts General Hospital, Boston

10087-6453

Columbia University Irving Medical Center, New York

All Listed Sponsors
lead

Regimmune Corporation

INDUSTRY

NCT04014790 - RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation | Biotech Hunter | Biotech Hunter